De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Johnson & Johnson Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joaquin Duato

Algemeen directeur

US$13.1m

Totale compensatie

Percentage CEO-salaris	11.4%
Dienstverband CEO	2yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joaquin Duato's beloning veranderd ten opzichte van Johnson & Johnson's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$13b
Jan 01 2023	US$13m	US$1m	US$18b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$21b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensatie versus markt: De totale vergoeding ($USD 13.10M ) Joaquin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de AR markt ($USD 5.68M ).

Compensatie versus inkomsten: De vergoeding van Joaquin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Joaquin Duato (60 yo)

2yrs

Tenure

US$13,099,487

Compensatie

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
Joseph Wolk	Executive VP & CFO	5.5yrs	US$8.82m	0.0022% ARS 7.0b
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12yrs	US$8.78m	0.0059% ARS 18.8b
Robert Decker	Controller & Chief Accounting Officer	4.1yrs	geen gegevens	0.00073% ARS 2.3b
James Swanson	Executive VP & Chief Information Officer	4.2yrs	geen gegevens	0.00038% ARS 1.2b
Jessica Moore	Vice President of Investor Relations	2.2yrs	geen gegevens	geen gegevens
Dirk Brinckman	Chief Compliance Officer	no data	geen gegevens	geen gegevens
Elizabeth Forminard	Executive VP & General Counsel	1.3yrs	geen gegevens	0.00023% ARS 738.9m
Peter Fasolo	Executive VP & Chief Human Resources Officer	7.8yrs	US$3.62m	0.0043% ARS 13.7b
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	geen gegevens	geen gegevens
William Hait	Executive VP	17yrs	geen gegevens	0.0036% ARS 11.6b
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	5.5yrs	geen gegevens	0.0027% ARS 8.8b

4.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DJNJ2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
D. Davis	Independent Director	9.6yrs	US$350.00k	geen gegevens
Anne Mulcahy	Lead Independent Director	15yrs	US$410.00k	0.00033% ARS 1.1b
Hubert Joly	Independent Director	4.1yrs	US$340.00k	0.00021% ARS 674.7m
Marillyn Hewson	Independent Director	4.8yrs	US$353.59k	0.00012% ARS 385.5m
Paula Johnson	Independent Director	less than a year	geen gegevens	0% ARS 0
Mark McClellan	Independent Director	10.3yrs	US$320.00k	geen gegevens
Mary Beckerle	Independent Director	8.6yrs	US$360.00k	geen gegevens
Darius Adamczyk	Independent Director	1.9yrs	US$300.16k	0.000040% ARS 128.5m
Jennifer Doudna	Independent Director	5.8yrs	US$340.00k	geen gegevens
Mark Weinberger	Independent Director	4.1yrs	US$340.00k	geen gegevens
Nadja West	Independent Director	3.1yrs	US$340.00k	geen gegevens

4.4yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DJNJ2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Johnson & Johnson Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI

Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd